Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Short term Debt (2022 - 2025)

BioXcel Therapeutics has reported Short term Debt over the past 3 years, most recently at $24.9 million for Q4 2025.

  • Quarterly results put Short term Debt at $24.9 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $24.9 million (changed N/A YoY), and the annual figure for FY2025 was $24.9 million, changed.
  • Short term Debt for Q4 2025 was $24.9 million at BioXcel Therapeutics, up from $16.8 million in the prior quarter.
  • Over the last five years, Short term Debt for BTAI hit a ceiling of $24.9 million in Q4 2025 and a floor of $56000.0 in Q1 2022.
  • Median Short term Debt over the past 3 years was $730000.0 (2023), compared with a mean of $5.6 million.
  • Peak annual rise in Short term Debt hit 578.57% in 2023, while the deepest fall reached 171.38% in 2023.
  • BioXcel Therapeutics' Short term Debt stood at $422000.0 in 2022, then skyrocketed by 72.99% to $730000.0 in 2023, then skyrocketed by 3315.21% to $24.9 million in 2025.
  • The last three reported values for Short term Debt were $24.9 million (Q4 2025), $16.8 million (Q3 2025), and $11.2 million (Q2 2025) per Business Quant data.